Molecule Group plc (AIM: MOL), the AIM-listed company building a regulated UK ePharmacy platform through a buy-and-build strategy, has announced a board change with immediate effect on 13 November 2026. Andrew Houghton, currently Managing Director of Lands' End Europe Limited, joins as an independent Non-Executive Director, bringing digital commerce and consumer-brand expertise to the board. Simultaneously, Dr David Wong steps down as Non-Executive Director. The appointment comes as Molecule continues to develop its diversified ePharmacy platform following three acquisitions completed in March 2026.

Key Points

  • Molecule Group plc (AIM: MOL) is an AIM-listed company building a regulated UK ePharmacy through acquisitions
  • Andrew Houghton appointed as independent Non-Executive Director with immediate effect; Dr David Wong departs the board simultaneously
  • Houghton, aged 50, previously held senior roles at Nike Inc (July 2012 to May 2024), Unilever PLC, and spent 8 years at Accenture's management consulting practice
  • Investors may be watching how Houghton's digital and eCommerce background supports Molecule's ongoing buy-and-build acquisition pipeline

Andrew Houghton's Digital and Consumer-Brand Background at Nike and Unilever

The announcement states that Andrew Houghton held senior roles at Nike Inc from July 2012 to May 2024, and previously at Unilever PLC, where he established a new business unit to develop Unilever's UK eCommerce strategy. He also spent eight years at Accenture within the management consulting practice. Houghton currently serves as Managing Director of Lands' End Europe Limited, the European subsidiary of Lands' End Corporation, described in the announcement as a leading online clothing retailer. The company disclosed that Houghton has held no other directorships or partnerships in the past five years beyond his current Lands' End Europe role.

Dr David Wong Departs Molecule Group Board With Immediate Effect

Alongside the Houghton appointment, Molecule Group confirmed that Dr David Wong steps down from the board of directors with immediate effect. The announcement offers no further detail regarding the circumstances of Dr Wong's departure. The board expressed its thanks to Dr Wong for his contribution to the company and wished him well. The simultaneous nature of the two changes — one departure and one appointment — means the total number of directors has remained consistent, though the company did not disclose the current full composition of the board in this announcement.

Molecule's ePharmacy Platform Following CloudRx, Webmed and Hyperdrug Acquisitions

Molecule Group describes itself as building a leading regulated ePharmacy platform through a disciplined buy-and-build strategy. The company completed the acquisitions of CloudRx, Webmed, and Hyperdrug in March 2026, establishing what the announcement describes as a diversified, profitable platform spanning B2B prescription fulfilment and B2C digital pharmacy services. The group highlights a high proportion of recurring revenues and strong cash generation as key characteristics of its business model. Chair Susan Clement Davies commented in the announcement that Houghton's commercial, consumer-brand, and digital experience would be "invaluable" as the company grows and progresses its buy-and-build strategy.